Search
reboxetine (Vestra, Edronax, Prolift, Integrex, Norebox)
Indications: treatment of depression
Contraindications:
-> concurrent use of MAO inhibitor
-> separate by a 2 week washout
Dosage:
1) 4 mg PO BID
2) in the elderly, start 2 mg BID
2) maximum: 12 mg/day
Reduce dose by 50% with renal or hepatic dysfunction
Pharmacokinetics:
1) metabolized by cyt P450 3A4
2) inhibits cyt P450 3A4 & cyt P450 2D6
Adverse effects:
1) dry mouth
2) constipation
3) insomnia
4) sweating
5) vertigo
6) urinary hesitancy or retention
7) impotence
8) sinus tachycardia (> 100/min) > 20% (no other EKG abnormalities)
Drug interactions:
1) reduce reboxetine dose when administered concurrently with inhibitors of cyt P450 3A4
2) MAO inhibitors
Laboratory:
- reboxetine in serum/plasma
Mechanism of action:
-> inhibition of norepinephrine reuptake (transporter)
Interactions
drug interactions
drug adverse effects (more general classes)
Related
Na+ dependent noradrenaline transporter; norepinephrine transporter; NET; solute carrier family 6 member 2 (SLC6A2, NAT1, NET1, SLC6A5)
General
atypical antidepressant
Properties
MISC-INFO: elimination route LIVER
KIDNEY
Database Correlations
PUBCHEM correlations